A Phase II Single-Center Exploratory Study on the Efficacy and Safety of Neoadjuvant Chemotherapy Sequentially Combined with Sintilimab in Resectable EGFR-Mutant Stage II-IIIB Non-Squamous Non-Small Cell Lung Cancer Patients.

The article discusses a Phase II clinical trial, NCT06688656, focusing on neoadjuvant chemotherapy combined with sintilimab in EGFR-mutant non-squamous NSCLC patients. The trial aims to evaluate the efficacy and safety of this combination therapy in resectable lung cancer patients. The study involves a single-arm design with specific outcome measures related to disease progression and survival. The trial is set to enroll 30 participants and is scheduled for completion by March 31, 2028. [Extracted from the article]